氯帕胺结构式
|
常用名 | 氯帕胺 | 英文名 | Clopamide |
---|---|---|---|---|
CAS号 | 636-54-4 | 分子量 | 345.845 | |
密度 | 1.4±0.1 g/cm3 | 沸点 | N/A | |
分子式 | C14H20ClN3O3S | 熔点 | 244-246ºC | |
MSDS | N/A | 闪点 | N/A | |
符号 |
GHS08 |
信号词 | Danger |
氯帕胺用途Clopamide 是一种具有口服活性的噻嗪类利尿剂,可抑制钠耦合的氯离子共转运蛋白 SLC12A3。Clopamide 可用于高血压和心力衰竭的研究。 |
中文名 | 氯帕胺 |
---|---|
英文名 | Clopamide |
中文别名 | 氯哌酰胺 | 4-氯-N-(顺式-2,6-二甲基哌啶基)-3-氨基磺酰基苯甲酰胺 |
英文别名 | 更多 |
描述 | Clopamide 是一种具有口服活性的噻嗪类利尿剂,可抑制钠耦合的氯离子共转运蛋白 SLC12A3。Clopamide 可用于高血压和心力衰竭的研究。 |
---|---|
相关类别 | |
体外研究 | 氯丙胺由肾小管细胞主动分泌,真正的肾小管排泄分数(TTEF)值为10%[3]。 |
体内研究 | 清醒犬口服氯丙胺(0.5 mg/kg)和同时局部输注环孢素-A(1-10μg/min)后,缓激肽的静脉收缩反应减弱[4]。 |
参考文献 |
密度 | 1.4±0.1 g/cm3 |
---|---|
熔点 | 244-246ºC |
分子式 | C14H20ClN3O3S |
分子量 | 345.845 |
精确质量 | 345.091400 |
PSA | 100.88000 |
LogP | 1.59 |
外观性状 | 白色至淡黄色结晶粉末 |
折射率 | 1.613 |
储存条件 | 2-8°C |
海关编码 | 2935009090 |
---|---|
中文概述 | 2935009090 其他磺(酰)胺. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:35.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. I: Investigation of mobile phase and MS conditions.
Anal. Chim. Acta 853 , 637-46, (2014) The conditions for the analysis of selected doping substances by UHPSFC-MS/MS were optimized to ensure suitable peak shapes and maximized MS responses. A representative mixture of 31 acidic and basic ... |
|
Ultra high performance supercritical fluid chromatography coupled with tandem mass spectrometry for screening of doping agents. II: Analysis of biological samples.
Anal. Chim. Acta 853 , 647-59, (2014) The potential and applicability of UHPSFC-MS/MS for anti-doping screening in urine samples were tested for the first time. For this purpose, a group of 110 doping agents with diverse physicochemical p... |
|
Effects of pindolol, or a pindolol/clopamide combination preparation, on plasma lipid levels in essential hypertension. Hunter Hypertension Research Group.
Med. J. Aust. 150(11) , 646, 648, 651-2, (1989) In an open study that was conducted in general practice, 22 patients with previously-untreated mild hypertension received an average daily dose of 11.7 mg of pindolol over a 50-week study period. The ... |
EINECS 211-261-7 |
Brinaldix |
DT-327 |
4-Chloro-N-[(2R,6S)-2,6-dimethyl-1-piperidinyl]-3-sulfamoylbenzamide |
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,6-dimethyl-1-piperidinyl)-, cis- |
CLOPAMIDUM |
ChlosudiMepriMyl |
Adurix |
MFCD00941495 |
4-Chloro-N-(2,6-dimethylpiperidino)-3-sulfamoylbenzamide |
3-(aminosulfonyl)-4-chloro-N-(2,6-dimethylpiperidin-1-yl)benzamide |
Aquex |
4-Chloro-N-(2,6-dimethylpiperidin-1-yl)-3-sulfamoylbenzamide |
Benzamide, 3-(aminosulfonyl)-4-chloro-N-[(2R,6S)-2,6-dimethyl-1-piperidinyl]- |
Benzamide, 3-(aminosulfonyl)-4-chloro-N-(2,6-dimethyl-1-piperidinyl)- |
4-Chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide |